Morgan Stanley Reiterates Equalweight Rating on Moderna (MRNA)

Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)

Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $310.00 price target on Moderna (NASDAQ: MRNA).

The analyst comments "Todays announcement for positive phase III data for mRNA-1083, its combination flu + COVID-19 vaccine candidate, supports our outlook. Combination vaccines have the... More

Jefferies on Moderna (MRNA): 'Phase III Flu/Covid Combo looks good - could be on market in 2025'

Jefferies analyst Michael Yee reiterated a Buy rating and $180.00 price target on Moderna (NASDAQ: MRNA).

The analyst comments "Phase III data from MRNA's Covid+Flu combo vaccine today generally looks in-line with expectations and shows superior level of antibody titers in... More

Moderna (MRNA) Reports Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older

Moderna, Inc. (NASDAQ: MRNA) today announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial.

"Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems... More

Moderna (MRNA) Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval

Moderna, Inc. (NASDAQ: MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1.

"For four years, Moderna has consistently delivered vaccines that offer protection against COVID-19, and work is well underway to provide a vaccine targeting JN.1," said Stphane Bancel,... More

Moderna (MRNA) option implied volatility amid price movement

Moderna (NASDAQ: MRNA) 30-day option implied volatility is at 49; compared to its 52-week range of 40 to 66.

Piper Sandler Reiterates Overweight Rating on Moderna (MRNA)

Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $214.00 price target on Moderna (NASDAQ: MRNA).

The analyst commented, "VRBPAC recommended Monovalent JN.1 COVID Vaccine for 2024 Season. The FDA approved mRESVIA (mRNA-1345), which will be launched this fall. Management guided 2024 product sales... More